OpenAlex
PricingAboutJobs
Log inGet started
Work

Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA.

HTML

Year: 2011
Type: conference-abstract
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2011.29.15_suppl.4535
Authors: H. Kübler, T. Maurer, A. Stenzl, S. Feyerabend, U. Steiner, M. Schostak, W. Schultze-Seemann, F. vom Dorp, L. Pilla, G. Viatali, C. Hampel, S. Wedel, L. Trojan, K. Hiller, M. Sommerauer, D. Jocham, B. Scheel, T. Lander, K. Kallen, K. Miller
Language: English

Topic: Immunotherapy and Immune Responses
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: prostate cancer vaccine, intradermal vaccination, castration-resistant prostate cancer, metastatic prostate cancer, PSA, prostate stem cell antigen, prostate-specific membrane antigen, STEAP1, vaccine safety, immune response, antigen-specific T cells, NK cell activation, B cells, urinary retention, dose escalation, immunotherapy, tetramer analysis, ELISPOT
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2242153643
Cites:
Cited by: 32
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security